Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin polymerization inhibitors are a class of compounds that disrupt the formation of microtubules by preventing the polymerization of tubulin. The AS269 payload is an example of such an inhibitor, used as a cytotoxic agent in targeted cancer therapies, including antibody-drug conjugates (ADCs). These inhibitors bind at or near the colchicine binding site on tubulin, preventing proper spindle formation, blocking cell cycle progression and inducing apoptosis in rapidly dividing cancer cells. They offer potential advantages over traditional chemotherapies due to reduced susceptibility to common resistance pathways.
Inhibition of tubulin polymerization, leading to disruption of microtubule dynamics and mitotic spindle formation, ultimately inducing cell cycle arrest and apoptosis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin Polymerization Inhibitor (AS269 Payload) (None).